# A Study of SAR428926 in Patients With Advanced Solid Tumors

> **NCT02575781** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 34 (actual)

## Conditions studied

- Neoplasm Malignant

## Interventions

- **DRUG:** SAR428926

## Key facts

- **NCT ID:** NCT02575781
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-05
- **Primary completion:** 2018-06
- **Final completion:** 2018-06
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2018-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02575781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02575781, "A Study of SAR428926 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02575781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*